Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069484 | 1.00 | MAPT (0.47) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2072213 | 1.00 | MAPT (0.47) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2069701 | 1.00 | MAPT (0.47) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2069802 | 0.95 | CYP3A4 (0.45) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL7503993 | 0.95 | CYP3A4 (0.45) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2069030 | 0.95 | CYP3A4 (0.45) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2069028 | 0.95 | CYP3A4 (0.45) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2070355 | 0.90 | CYP3A4 (0.46) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2070356 | 0.90 | CYP3A4 (0.46) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 | |
| SCHEMBL2070800 | 0.90 | CYP3A4 (0.46) | MAPTMAPK1TDP1CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | MAPT 3761/4885MAPK1 2997/4885TDP1 4696/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | MAPT 3422/4885MAPK1 4428/4885TDP1 4297/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | MAPT 3761/4885MAPK1 2997/4885TDP1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.